Actively Recruiting
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Led by Peking University Cancer Hospital & Institute · Updated on 2023-09-06
140
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
CONDITIONS
Official Title
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Histopathologically confirmed recurrent, inoperable, or metastatic acral melanoma (stage III/IV)
- No previous systemic anti-tumor drug treatment
- Measurable disease based on RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate organ function
- Life expectancy greater than 12 weeks
- Provided written informed consent
You will not qualify if you...
- Receiving or have received additional chemotherapy, radiation, targeted therapy, or immunotherapy
- Known allergy to macromolecular protein preparations or components of study drugs
- Having other malignant tumors except cured skin basal cell carcinoma or cervical carcinoma in situ
- Active autoimmune disease or history of autoimmune disease
- Uncontrolled significant heart disease including NYHA class III or higher heart failure, unstable angina, recent myocardial infarction within 1 year, or serious arrhythmias requiring treatment
- Received live vaccine within 4 weeks before first study dose
- Pregnant or breastfeeding
- Determined unsuitable by principal investigator or physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jun Guo, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here